167 related articles for article (PubMed ID: 24038567)
1. Treatment of hepatitis C monoinfection in adults--Dutch national guidelines.
Lamers MH; Broekman MM; Boucher CA; Brouwer JT; Burger DM; van Hoek B; Hoepelman AI; de Knegt RJ; Reesink HW; Drenth JP; ; ;
Neth J Med; 2013 Sep; 71(7):377-85. PubMed ID: 24038567
[TBL] [Abstract][Full Text] [Related]
2. UK consensus guidelines for the use of the protease inhibitors boceprevir and telaprevir in genotype 1 chronic hepatitis C infected patients.
Ramachandran P; Fraser A; Agarwal K; Austin A; Brown A; Foster GR; Fox R; Hayes PC; Leen C; Mills PR; Mutimer DJ; Ryder SD; Dillon JF
Aliment Pharmacol Ther; 2012 Mar; 35(6):647-62. PubMed ID: 22296568
[TBL] [Abstract][Full Text] [Related]
3. Direct-acting antiviral therapies for hepatitis C genotype 1 infection: a multiple treatment comparison meta-analysis.
Cooper C; Lester R; Thorlund K; Druyts E; El Khoury AC; Yaya S; Mills EJ
QJM; 2013 Feb; 106(2):153-63. PubMed ID: 23159839
[TBL] [Abstract][Full Text] [Related]
4. Effectiveness of telaprevir or boceprevir in treatment-experienced patients with HCV genotype 1 infection and cirrhosis.
Hézode C; Fontaine H; Dorival C; Zoulim F; Larrey D; Canva V; De Ledinghen V; Poynard T; Samuel D; Bourliere M; Alric L; Raabe JJ; Zarski JP; Marcellin P; Riachi G; Bernard PH; Loustaud-Ratti V; Chazouilleres O; Abergel A; Guyader D; Metivier S; Tran A; Di Martino V; Causse X; Dao T; Lucidarme D; Portal I; Cacoub P; Gournay J; Grando-Lemaire V; Hillon P; Attali P; Fontanges T; Rosa I; Petrov-Sanchez V; Barthe Y; Pawlotsky JM; Pol S; Carrat F; Bronowicki JP;
Gastroenterology; 2014 Jul; 147(1):132-142.e4. PubMed ID: 24704719
[TBL] [Abstract][Full Text] [Related]
5. [Treatment of chronic hepatitis viral C: new associations].
Ouzan D
Presse Med; 2013 Jun; 42(6 Pt 1):977-82. PubMed ID: 23021659
[TBL] [Abstract][Full Text] [Related]
6. [Use of boceprevir and telaprevir in patients with hepatitis C virus infection (practical considerations)].
Crespo G; Lens S
Gastroenterol Hepatol; 2012 May; 35(5):337-43. PubMed ID: 22349607
[TBL] [Abstract][Full Text] [Related]
7. Cost utility of telaprevir-PR (peginterferon-ribavirin) versus boceprevir-PR and versus PR alone in chronic hepatitis C in The Netherlands.
Vellopoulou A; van Agthoven M; van der Kolk A; de Knegt RJ; Berdeaux G; Cure S; Bianic F; Lamotte M
Appl Health Econ Health Policy; 2014 Dec; 12(6):647-59. PubMed ID: 25103219
[TBL] [Abstract][Full Text] [Related]
8. Triple therapy with telaprevir: results in hepatitis C virus-genotype 1 infected relapsers and non-responders.
Forestier N; Zeuzem S
Liver Int; 2012 Feb; 32 Suppl 1():44-50. PubMed ID: 22212571
[TBL] [Abstract][Full Text] [Related]
9. Telaprevir versus boceprevir in chronic hepatitis C: a meta-analysis of data from phase II and III trials.
Sitole M; Silva M; Spooner L; Comee MK; Malloy M
Clin Ther; 2013 Feb; 35(2):190-7. PubMed ID: 23369368
[TBL] [Abstract][Full Text] [Related]
10. Therapy with boceprevir or telaprevir in HIV/hepatitis C virus co-infected patients to treat recurrence of hepatitis C virus infection after liver transplantation.
Antonini TM; Furlan V; Teicher E; Haim-Boukobza S; Sebagh M; Coilly A; Bonhomme-Faivre L; Roque-Afonso AM; Vittecoq D; Samuel D; Taburet AM; Duclos-Vallée JC
AIDS; 2015 Jan; 29(1):53-8. PubMed ID: 25387314
[TBL] [Abstract][Full Text] [Related]
11. Impact of HCV protease-inhibitor-based triple therapy for chronic HCV genotype 1 infection.
Ferenci P; Reddy KR
Antivir Ther; 2011; 16(8):1187-201. PubMed ID: 22155901
[TBL] [Abstract][Full Text] [Related]
12. Phase III results of Boceprevir in treatment naïve patients with chronic hepatitis C genotype 1.
Manns MP; Markova AA; Calle Serrano B; Cornberg M
Liver Int; 2012 Feb; 32 Suppl 1():27-31. PubMed ID: 22212568
[TBL] [Abstract][Full Text] [Related]
13. Triple therapy with first-generation protease inhibitors for patients with genotype 1 chronic hepatitis C: recommendations of the Italian association for the study of the liver (AISF).
; Coco B; Caraceni P; Aghemo A; Bitetto D; Bruno R; Ciancio A; Marzioni M; Petta S; Rendina M; Valenti L;
Dig Liver Dis; 2014 Jan; 46(1):18-24. PubMed ID: 24119482
[TBL] [Abstract][Full Text] [Related]
14. The results of Phase III clinical trials with telaprevir and boceprevir presented at the Liver Meeting 2010: a new standard of care for hepatitis C virus genotype 1 infection, but with issues still pending.
Pawlotsky JM
Gastroenterology; 2011 Mar; 140(3):746-54. PubMed ID: 21255572
[No Abstract] [Full Text] [Related]
15. Treatment failure with new hepatitis C drugs.
Soriano V; Vispo E; Poveda E; Labarga P; Barreiro P
Expert Opin Pharmacother; 2012 Feb; 13(3):313-23. PubMed ID: 22242928
[TBL] [Abstract][Full Text] [Related]
16. Triple therapy with first generation HCV protease inhibitors: lead-in or no lead-in phase?
Pascale A; Serfaty L
J Hepatol; 2013 Feb; 58(2):391-4. PubMed ID: 23063419
[TBL] [Abstract][Full Text] [Related]
17. [Triple therapy in cirrhotic patients and those with advanced fibrosis: relevant aspects in clinical practice].
Albillos A; Luis Calleja J; Molina E; Planas R; Romero-Gómez M; Turnes J; Hernández-Guerra M
Gastroenterol Hepatol; 2014 Jul; 37 Suppl 1():13-22. PubMed ID: 25907434
[TBL] [Abstract][Full Text] [Related]
18. [Hungarian consensus guideline for the diagnosis and treatment of B, C, and D viral hepatitis].
Makara M; Horváth G; Gervain J; Pár A; Szalay F; Telegdy L; Tornai I; Ujhelyi E; Hunyady B
Orv Hetil; 2012 Mar; 153(10):375-94. PubMed ID: 22370225
[TBL] [Abstract][Full Text] [Related]
19. Impact of ribavirin on HCV replicon RNA decline during treatment with interferon-α and the protease inhibitors boceprevir or telaprevir.
Hofmann WP; Chung TL; Osbahr C; Susser S; Karey U; Mihm U; Welsch C; Lötsch J; Sarrazin C; Zeuzem S; Herrmann E
Antivir Ther; 2011; 16(5):695-704. PubMed ID: 21817191
[TBL] [Abstract][Full Text] [Related]
20. Hepatitis C virus NS3 protease genotyping and drug concentration determination during triple therapy with telaprevir or boceprevir for chronic infection with genotype 1 viruses, southeastern France.
Aherfi S; Solas C; Motte A; Moreau J; Borentain P; Mokhtari S; Botta-Fridlund D; Dhiver C; Portal I; Ruiz JM; Ravaux I; Bregigeon S; Poizot-Martin I; Stein A; Gérolami R; Brouqui P; Tamalet C; Colson P
J Med Virol; 2014 Nov; 86(11):1868-76. PubMed ID: 25052594
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
